Guggenheim Initiates Coverage On Abivax with Buy Rating, Announces Price Target of $50
Portfolio Pulse from Benzinga Newsdesk
Guggenheim analyst Yatin Suneja initiates coverage on Abivax (NASDAQ:ABVX) with a Buy rating and a price target of $50.
April 29, 2024 | 10:22 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Guggenheim analyst Yatin Suneja has initiated coverage on Abivax with a Buy rating and set a price target of $50.
The initiation of coverage by a reputable analyst with a Buy rating and a significant price target suggests a positive outlook for Abivax's stock. This could lead to increased investor interest and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100